|Day Low/High||34.35 / 35.45|
|52 Wk Low/High||9.51 / 23.30|
The most recent short interest data has been released for the 03/31/2017 settlement date, which shows a 406,576 share increase in total short interest for Supernus Pharmaceuticals Inc , to 3,053,345, an increase of 15.36% since 03/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Trokendi XR is the Leading Extended-Release Topiramate Product and Brand of Topiramate
Broad strength and good tone mark action.
Here's why to check out Dynavax Technologies as well Lexicon, Supernus and Acadia Pharmaceuticals.
Demographic trends that boosted big gains in prior years haven't gone away.
This is the time of the year when many moves are made for tax reasons.
The number of new 12-month highs has climbed to 240.
U.S. Court of Appeals Affirms District Court's Decision on Oxtellar XR®
Jim Cramer urges caution with phamaceutical companies Supernus and Ariad
Jim Cramer explains the rotation, looks ahead to next week.
In trading on Thursday, shares of Supernus Pharmaceuticals Inc crossed below their 200 day moving average of $18.67, changing hands as low as $18.00 per share. Supernus Pharmaceuticals Inc shares are currently trading off about 8.3% on the day.